INDIANAPOLIS, May 16, 2011 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) will present data from more than 30 studies
At ASCO, Lilly will present the latest research results on ALIMTA® (pemetrexed for injection) and GEMZAR® (gemcitabine for injection), as well as ERBITUX® (cetuximab) with partners Bristol-Myers Squibb and Merck KGaA.
"Lilly Oncology is committed to exploring innovations that improve outcomes for all people living with cancer," said Richard Gaynor, M.D., vice president, product development and medical affairs for Lilly Oncology. "We believe that data from PARAMOUNT, and our other studies at ASCO, demonstrate Lilly's focus on tailored therapies, and commitment to addressing unmet needs in cancer care."
ALIMTA Oral Abstract Session:
This press release contains forward-looking statements about the potential of ALIMTA and reflects Lilly's current beliefs. However, as with any pharmaceutical product, there are substantial risks and uncertainties in the process of development and commercialization. There is no guarantee that the product will continue to be commercially successful. For further discussion of these and other risks and uncertainties, see Lilly's filings with the United States Securities and Exchange Commission. Lilly undertakes no duty to update forward-looking statements.
(Logo: http://photos.prnewswire.com/prnh/20031219/LLYLOGO )
SOURCE Eli Lilly and Company
Subscribe to our Free Newsletters!
Sea food allergy is the adverse response of the body''s immune system to the proteins present in ...
Yellow fever is a hemorrhagic fever that is transmitted by infected mosquitoes and it can lead to ...
Routes of drug administration play a major role in a medical treatment. Selecting a right route of ...View All